Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

Biotech Tweets of the Week: Gilead Sciences and Orexigen

By Brian Orelli, PhD - Mar 21, 2014 at 8:49PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Two tweets highlight expectations of Gilead Sciences and Orexigen.

Not on twitter? (That should include some of you.)

Not able to keep up with the high volume of biotech tweets? (That should include most of the rest of you.)

Fool contributor Brian Orelli and health-care bureau chief Max Macaluso are here to catch you up (at least a little). In the video below, the duo discusses two recent tweets they found interesting.

In the first, ISI analyst Mark Schoenebaum points out that the P/E for Gilead Sciences ( GILD 1.35% ) has remained relatively unchanged despite the substantial run-up the company has experienced.

In the second tweet, Dan Loncar makes an observation that Orexigen (NASDAQ: OREX) says it's "highly confident" in an FDA approval for its obesity drug, but only "confident" in an approval by European regulators. The wording isn't particularly surprising given that its competitors -- VIVUS' ( VVUS ) Qsymia and Arena Pharmaceuticals' ( ARNA -1.54% ) Belviq -- have gotten approved stateside, but not in Europe.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Gilead Sciences, Inc. Stock Quote
Gilead Sciences, Inc.
$69.86 (1.35%) $0.93
Arena Pharmaceuticals, Inc. Stock Quote
Arena Pharmaceuticals, Inc.
$53.65 (-1.54%) $0.84
VIVUS, Inc. Stock Quote

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/01/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.